… trial of sepofarsen for the treatment of CEP290 -mediated Leber congenital amaurosis 10 (LCA10) did not meet its … 30 days following the presentation date. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital amaurosis (LCA) is the most common cause of …
… Business Operations and Program Updates Sepofarsen for Leber congenital amaurosis 10 (LCA10): The Company expects to … statements appearing at the end of this release. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
… 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet the … later in H1 2022 on our website at www.proqr.com . About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
… and Program Updates Sepofarsen for CEP290-mediated Leber congenital amaurosis 10 (LCA10): The Company expects to … statements appearing at the end of this release. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
… Program Updates Sepofarsen, lead clinical candidate for Leber congenital amaurosis 10 (LCA10) in the Phase 2/3 … statements appearing at the end of this release. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
… Phase 2/3 Illuminate trial in people with CEP290 -mediated Leber congenital amaurosis 10, or LCA10, a severe inherited … 30 days following the presentation date. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th
… Business Operations and Program Updates Sepofarsen for Leber congenital amaurosis 10 (LCA10): In April, the first … statements appearing at the end of this release. About Leber Congenital Amaurosis 10 (LCA10) Leber congenital amaurosis (LCA) is the most common cause of …